Jul 26, 2022 8:30am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update
Jun 08, 2022 7:00am EDT Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia
May 03, 2022 4:01pm EDT Rigel Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 26, 2022 8:30am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update
Mar 08, 2022 8:05am EST Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology
Mar 01, 2022 4:01pm EST Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Feb 22, 2022 8:30am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update
Dec 21, 2021 8:30am EST Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia
